NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome

Richter syndrome (RS) is associated with chemotherapy resistance and a poor historical median overall survival (OS) of 8-10 months. We conducted a phase II trial of standard CHOP-21 (cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 d) with ofatumumab induction (Cycle 1: 300 mg day 1...

Full description

Bibliographic Details
Main Authors:	Eyre, T, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, Mccarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamatopoulos, B, Love, S, Wotherspoon, A, Schuh, A
Format:	Journal article
Language:	English
Published:	John Wiley & Sons Ltd 2016

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome

Similar Items